Alchemab Therapeutics
AI drug discovery / antibodies, Cambridge
AI-driven discovery of protective human antibodies for neurodegeneration and cancer. It raised £25m in its Series A in July 2026. It has 1 role open, 0 of them in the UK.
Backed by British Business Bank, Eli Lilly, RA Capital and SV Health Investors. Total raised ~$114m+.
On the Home Office register of licensed visa sponsors.
- 19 daystypical age of an open role
- 0roles open for more than 60 days
- 0roles taken down since we started tracking
- 0%of roles list a salary
Open roles
1 live today- Salary not listed19 days agoApply
Open roles over time
Hiring momentum
Roles per weekAdded (by posting date)Closed (removed from the board)In the news (hover for headline)
Open roles by function
Open roles by team
As the company labels themIn the news
All 22 stories- LeadershipBioSpace, 10 Sept 2026Alchemab Therapeutics Expands Leadership Team, Appointing Dr Ben Porter-Brown as CMO to Propel the Clinical Advancement of Its Pipeline
- OtherHealthcare Today, 22 Jul 2026Capital raising in healthtech: Healome Therapeutics, Alchemab Therapeutics
- Fundingcambridgeindependent.co.uk, 16 Jul 2026£25m Series A boost is a huge vote of support for Alchemab’s resiliomics
- FundingBusiness Wire, 8 Jul 2026Alchemab Therapeutics Announces Largest Ever Life Sciences Investment From British Business Bank to Advance AI-Enabled Clinical Pipeline of Next Generation Human-Derived Antibodies
- OtherCambridge Independent, 25 Mar 2026Alchemab welcomes new CBO with senior Sanofi expertise
- OtherHealthInvestor UK, 21 Mar 2026Alchemab Therapeutics: Ulrich Wendt